Targeting a specific signaling pathway to treat kidney cancer
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer
This study is looking at a new way to treat clear cell kidney cancer by focusing on a protein called TBK1, which could help create treatments that target cancer cells more effectively while keeping your immune system safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10909301 on NIH RePORTER |
What this research studies
This research investigates a new therapeutic target for clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that is often resistant to existing treatments. The study focuses on the role of TANK Binding Kinase 1 (TBK1) in cancer cell growth and how its regulation can lead to more effective therapies. By identifying TBK1 regulators, the research aims to develop inhibitors that specifically target cancer cells without affecting the immune system. This approach could provide a more tailored treatment option for patients with VHL-deficient kidney cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with VHL deficiency.
Not a fit: Patients with other types of kidney cancer or those without VHL deficiency may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with clear cell renal cell carcinoma.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Zhang, Qing — Ut Southwestern Medical Center
- Study coordinator: Zhang, Qing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.